MedPath

Effect of Antihypertensive Drugs on Glaucoma Patients

Conditions
Glaucoma
Registration Number
NCT04943107
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Brief Summary

It has been reported that among Asian non-glaucomatous, antihypertensive medications were associated with retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness. In order to explore whether antihypertensive medications would influence the neuropathy among glaucomatous population, we designed a cross-sectional observational study to analyze the retinal status among glaucoma patients with use of antihypertensive medication.

Detailed Description

we designed a cross-sectional obeservational study to analyze the retinal status among glaucoma patients with use of hyertensive medication.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  • age no less than 18 years

    • best corrected visual acuity better than decimal 0.3
Exclusion Criteria
  • secondary glaucoma

    • secondary hypertension
    • glaucoma-related operation history
    • pregnancy or lactation period
    • uncooperative with retinal examination
    • severe opacity with refracting media in eye
    • severe retinal diseases and neuropathy
    • congenital retinal optic nerve abnormality
    • other systemic diseases that influence hypertension and glaucoma assessment

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
retinal nerve fiber layer thicknesswithin 3 months from recruitment

retinal nerve fiber layer thickness measured by optical coherence tomography

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

2nd Affiliated Hospital, School of Medicine, Zhejiang University

🇨🇳

Hangzhou, Zhejiang, China

2nd Affiliated Hospital, School of Medicine, Zhejiang University
🇨🇳Hangzhou, Zhejiang, China
Kaijun Wand, MD
Contact
+86 1360052917
wkj992@126.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.